KPD Consolidation After ASCT in NDMM Patients

This study aims to evaluate the efficacy and safety of post-transplant consolidation therapy with the KPD regimen (carfilzomib, pomalidomide, and dexamethasone) versus no consolidation, followed by maintenance therapy, in patients with transplant-eligible newly diagnosed multiple myeloma (TE-NDMM). The primary goal is to compare minimal residual disease (MRD) negativity rates and overall treatment outcomes between the two groups.

Trial Details

NCT ID
NCT06879379
Phase
PHASE2 / PHASE3
Sponsor
Peking University People's Hospital
Status
RECRUITING
Cancer Type
Newly Diagnosed Multiple Myeloma
Interventions
  • KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Age ≥18 years.
  • Newly diagnosed MM eligible for transplantation.
  • Received upfront triplet or quadraplet induction regimen.
  • Received upfront ASCT after induction.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →